Management of Severe LV Systolic Dysfunction with CKD Stage 3

First-Line Pharmacotherapy

The European Society of Cardiology recommends ACE inhibitors or ARBs as first-line therapy for all patients with severe LV systolic dysfunction and CKD stage 3, with careful monitoring of renal function and potassium levels 3, 4
Beta-blockers should be used in conjunction with ACE inhibitors/ARBs, starting at the lowest effective dose to achieve heart rate control, as recommended by the European Heart Journal 5, 3
SGLT2 inhibitors are strongly recommended for patients with LV systolic dysfunction and CKD stage 3, as they reduce CKD progression and heart failure hospitalizations, according to Kidney International 6, 4
Mineralocorticoid receptor antagonists (MRAs) should be added to the regimen for symptomatic heart failure with reduced ejection fraction, as recommended by the European Heart Journal 2

The European Society of Cardiology recommends a target blood pressure of 130-139 mmHg systolic for patients with CKD stage 3 2
For patients with both heart failure and CKD, individualize blood pressure targets based on tolerance, with careful monitoring for hypotension, as recommended by the European Heart Journal 2, 3
Avoid excessive blood pressure reduction (systolic BP <120 mmHg) in patients with severe LV dysfunction and CKD, according to the European Heart Journal 2

The Kidney International recommends statin therapy for all patients aged ≥50 years with CKD stage 3 to reduce cardiovascular risk 1, 3
For patients aged 18-49 years with CKD stage 3, statin therapy is recommended if they have known coronary disease, diabetes, prior stroke, or 10-year cardiovascular risk >10%, as recommended by Kidney International 1, 3
Low-dose aspirin is recommended for secondary prevention in patients with established cardiovascular disease, according to Kidney International 1, 6

For patients with concomitant atrial fibrillation, non-vitamin K antagonist oral anticoagulants (NOACs) are preferred over vitamin K antagonists, with appropriate dose adjustment for CKD stage 3, as recommended by Kidney International and the European Heart Journal 6, 5
For rate control in atrial fibrillation with LV systolic dysfunction, use the smallest dose of beta-blocker to achieve rate control, according to the European Heart Journal 5

A plant-based "Mediterranean-style" diet is recommended to reduce cardiovascular risk, as suggested by Kidney International 1, 3
Sodium restriction is essential for both heart failure and CKD management, according to Praxis Medical Insights 3, 4